Document Type : Research Articles
Authors
1
Faculty of Public Health, Khon Kaen Univerisity, Khon Kaen Province, Thailand.
2
Faculty of Public Health, University of Medicine and Pharmacy, Hue University, Hue City, Vietnam.
3
Breast Department, Danang Oncology Hospital, Danang city, Vietnam.
4
ASEAN Cancer Epidemiology and Prevention Research Group (ACEP), Thailand.
Abstract
Background: Breast cancer (BC) is one of the most common cancers worldwide; however, there is a lack of comprehensive data on survival outcomes and prognostic factors in Central Vietnam. This study aimed to estimate overall survival (OS) rates and identify key prognostic factors associated with mortality among BC patients in this region. Methods: This ambidirectional cohort study included 1,213 patients newly diagnosed with BC at Danang Oncology Hospital between January 2019 and December 2023. OS rates at 1, 3, and 5 years were estimated using the Kaplan-Meier method, and survival differences across molecular subtypes and TNM stages were evaluated using the log-rank test. Prognostic factors for mortality were assessed using a multivariable Cox proportional hazards model. Results: The 1-, 3-, and 5-year OS rates were 97.4%, 91.0%, and 86.0%, respectively. The Luminal A subtype had the highest 5-year OS rate (91.5%), while the triple-negative subtype had the lowest (76.9%). Patients with stage IV disease had a 5-year OS rate of 29.5%. Significant predictors of higher mortality included unemployment [adjusted hazard ratio (aHR) 1.59], liver diseases (aHR 3.06), progesterone receptor-negative status (aHR 2.20), Ki-67 index ≥30% (aHR 2.13), and TNM stage III–IV (aHR 10.27). Surgical intervention was associated with a reduced risk of mortality (aHR 0.40). Conclusions: The study found relatively high OS rates in this cohort. However, advanced stage, unfavorable tumor characteristics, comorbidities, and socioeconomic disadvantage were associated with worse outcomes. Collaborative multicenter research using standardized data collection is necessary to validate and expand these findings across diverse settings, ultimately supporting efforts to improve survival outcomes in BC patients.
Keywords
Main Subjects
)